FDA grants 12-year exclusivity to Flublok; Emergent BioSolutions' Ebola candidate enters Ph I;

> The FDA granted 12-year exclusivity to Protein Sciences' Flublok, which means no product similar to Flublok can be approved by the FDA before Jan. 16, 2025. Release

> Emergent BioSolutions' ($EBS) investigational Ebola vaccine, produced using ProBioGen's platform, has entered clinical trials at Oxford University in the U.K. Release

> Griffith University's Institute for Glycomics has developed a combination vaccine that may beat Streptococcus A infections. Human trials may begin as early as 2016. More

> Soligenix announced data demonstrating a heat-stable formulation of an HPV vaccine. Release

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.